ArticleNeurochemical research2026
Role of the miR-340-5p/IRF1/USP18 Axis in Neuroinflammation Associated with Epilepsy.
Article in Neurochemical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Epilepsy is a prevalent neurological disorder, in which maladaptive neuroinflammation critically contributes to epileptogenesis. In this study, we identified a previously unrecognized signaling axis that regulates inflammatory responses and inflammatory cell death in experimental epilepsy. Integrated bioinformatic analyses of the GSE73878 and GSE18740 datasets, together with transcription factor and microRNA prediction databases, highlighted USP18 and its upstream regulators as key candidates. Functional and mechanistic validations were performed using lipopolysaccharide-stimulated BV2 microglia and pentylenetetrazole-induced mouse seizure models. Seizure severity and epileptic phenotypes were confirmed using the Racine scale assessments and EEG recordings. USP18 was markedly upregulated under epileptic conditions accompanied by increased pro-inflammatory cytokine release, apoptosis, and pyroptosis. Silencing USP18 attenuated neuroinflammation and reduced seizure severity. Mechanistically, interferon regulatory factor 1 (IRF1) was identified as a direct transcriptional activator of USP18, whereas miR-340-5p suppressed USP18 expression by targeting IRF1, thereby mitigating inflammatory signaling and neuronal injury. Collectively, these findings reveal a novel regulatory pathway linking microRNA-mediated control, interferon-responsive transcription, and inflammatory effector mechanisms in epilepsy, and suggest that targeting the miR-340-5p/IRF1/USP18 axis may represent a promising disease-modifying therapeutic strategy.
Indexed as
Identifiers
42430078What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.